RG 7258 / Roche - LARVOL DELTA

Research status and prospects of TSLP inhibitors in the treatment of asthma [Google translation] (med.china.com.cn) - "The TSLP target drugs that have entered the clinical stage are only a few biological drugs, such as the fully human IgG2λ monoclonal antibody Tezepelumab...and the inhalation developed jointly by Novartis and MorphoSys Dosage type—Immunoglobulin G1/λ subtype antibody fragment CSJ-117...and other recombinant humanized IgG1 monoclonal antibodies such as Merck MK-8226, Roche RG7258, Astellas ASP7266....Bifunctional drugs...provide an exciting new method for the treatment of asthma....The monovalent bispecific antibody Zweimab and the bivalent bispecific antibody Doppelmab, which are used to target TSLP and IL-13 due to the huge overlap of signal pathways, have been designed, developed and characterized."

Review • Asthma • Respiratory Diseases